These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 23982883)

  • 1. XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: suitability as a biomarker for patient selection.
    Hatch SB; Swift LP; Caporali S; Carter R; Hill EJ; MacGregor TP; D'Atri S; Middleton MR; McHugh PJ; Sharma RA
    Int J Cancer; 2014 Mar; 134(6):1495-503. PubMed ID: 23982883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.
    Arora S; Kothandapani A; Tillison K; Kalman-Maltese V; Patrick SM
    DNA Repair (Amst); 2010 Jul; 9(7):745-53. PubMed ID: 20418188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression.
    Usanova S; Piée-Staffa A; Sied U; Thomale J; Schneider A; Kaina B; Köberle B
    Mol Cancer; 2010 Sep; 9():248. PubMed ID: 20846399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers.
    Mesquita KA; Alabdullah M; Griffin M; Toss MS; Fatah TMAA; Alblihy A; Moseley P; Chan SYT; Rakha EA; Madhusudan S
    Gynecol Oncol; 2019 May; 153(2):416-424. PubMed ID: 30797591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of endonucleases XPF and XPG in nucleotide excision repair of platinated DNA and cisplatin/oxaliplatin cytotoxicity.
    Graf N; Ang WH; Zhu G; Myint M; Lippard SJ
    Chembiochem; 2011 May; 12(7):1115-23. PubMed ID: 21452186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue.
    Bhagwat NR; Roginskaya VY; Acquafondata MB; Dhir R; Wood RD; Niedernhofer LJ
    Cancer Res; 2009 Sep; 69(17):6831-8. PubMed ID: 19723666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of the ERCC1-XPF structure-specific endonuclease to overcome cancer chemoresistance.
    McNeil EM; Astell KR; Ritchie AM; Shave S; Houston DR; Bakrania P; Jones HM; Khurana P; Wallace C; Chapman T; Wear MA; Walkinshaw MD; Saxty B; Melton DW
    DNA Repair (Amst); 2015 Jul; 31():19-28. PubMed ID: 25956741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells.
    Arora S; Heyza J; Zhang H; Kalman-Maltese V; Tillison K; Floyd AM; Chalfin EM; Bepler G; Patrick SM
    Oncotarget; 2016 Nov; 7(46):75104-75117. PubMed ID: 27650543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ERCC1, MLH1, MSH2, MSH6, and βIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma.
    Ting S; Mairinger FD; Hager T; Welter S; Eberhardt WE; Wohlschlaeger J; Schmid KW; Christoph DC
    Clin Lung Cancer; 2013 Sep; 14(5):558-567.e3. PubMed ID: 23810210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defects in interstrand cross-link uncoupling do not account for the extreme sensitivity of ERCC1 and XPF cells to cisplatin.
    De Silva IU; McHugh PJ; Clingen PH; Hartley JA
    Nucleic Acids Res; 2002 Sep; 30(17):3848-56. PubMed ID: 12202770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. XPF-ERCC1 Blocker Improves the Therapeutic Efficacy of 5-FU- and Oxaliplatin-Based Chemoradiotherapy in Colorectal Cancer.
    Huang MY; Huang YJ; Cheng TL; Jhang WY; Ke CC; Chen YT; Kuo SH; Lin IL; Huang YH; Chuang CH
    Cells; 2023 May; 12(11):. PubMed ID: 37296596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the DNA Repair Endonuclease ERCC1-XPF with Green Tea Polyphenol Epigallocatechin-3-Gallate (EGCG) and Its Prodrug to Enhance Cisplatin Efficacy in Human Cancer Cells.
    Heyza JR; Arora S; Zhang H; Conner KL; Lei W; Floyd AM; Deshmukh RR; Sarver J; Trabbic CJ; Erhardt P; Chan TH; Dou QP; Patrick SM
    Nutrients; 2018 Nov; 10(11):. PubMed ID: 30400270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin regulates the MAPK kinase pathway to induce increased expression of DNA repair gene ERCC1 and increase melanoma chemoresistance.
    Li W; Melton DW
    Oncogene; 2012 May; 31(19):2412-22. PubMed ID: 21996734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RPA activates the XPF-ERCC1 endonuclease to initiate processing of DNA interstrand crosslinks.
    Abdullah UB; McGouran JF; Brolih S; Ptchelkine D; El-Sagheer AH; Brown T; McHugh PJ
    EMBO J; 2017 Jul; 36(14):2047-2060. PubMed ID: 28607004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Translational study identifies XPF and MUS81 as predictive biomarkers for oxaliplatin-based peri-operative chemotherapy in patients with esophageal adenocarcinoma.
    MacGregor TP; Carter R; Gillies RS; Findlay JM; Kartsonaki C; Castro-Giner F; Sahgal N; Wang LM; Chetty R; Maynard ND; Cazier JB; Buffa F; McHugh PJ; Tomlinson I; Middleton MR; Sharma RA
    Sci Rep; 2018 May; 8(1):7265. PubMed ID: 29739952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Killing of chronic lymphocytic leukemia by the combination of fludarabine and oxaliplatin is dependent on the activity of XPF endonuclease.
    Zecevic A; Sampath D; Ewald B; Chen R; Wierda W; Plunkett W
    Clin Cancer Res; 2011 Jul; 17(14):4731-41. PubMed ID: 21632856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy.
    Li P; Fang YJ; Li F; Ou QJ; Chen G; Ma G
    Br J Cancer; 2013 Apr; 108(6):1238-44. PubMed ID: 23481186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Function and Interactions of ERCC1-XPF in DNA Damage Response.
    Faridounnia M; Folkers GE; Boelens R
    Molecules; 2018 Dec; 23(12):. PubMed ID: 30563071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of domains for protein-protein interaction of nucleotide excision repair proteins modifies cancer cell sensitivity to platinum derivatives and genomic stability.
    Jordheim LP; Cros-Perrial E; Matera EL; Bouledrak K; Dumontet C
    Clin Exp Pharmacol Physiol; 2014 Oct; 41(10):817-24. PubMed ID: 25115435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy.
    McNeil EM; Melton DW
    Nucleic Acids Res; 2012 Nov; 40(20):9990-10004. PubMed ID: 22941649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.